Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1785-1794

  Tonino, Sanne H ^a   Van De Berg, Pablo J ^a   Yong, Si La ^a   Ten Berge, Ineke J ^a   Kersten, Marie José ^a   Van Lier, René A W ^a   Van Oers, Marinus H ^a   Kater, Arnon P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

B cell non Hodgkin lymphoma; CLL; CMV; Effector T cells; PD 1

Indexed keywords

CD27 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; EFFECTOR CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

AGED; ANTIGENS, CD45; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84865029103     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.673224     Document Type: Article

References (41)

1. C aligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: A bird of a diff erent feather. J Clin Oncol 1999;17:399-408.
2. H amblin AD, Hamblin TJ. The immunodefi ciency of chronic lymphocytic leukaemia. Br Med Bull 2008;87:49-62.
3. D unn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
4. Serrano D, Monteiro J, Allen SL, et a l. Clonal expansion within the CD4- CD57- and CD8- CD57- T cell subsets in chronic lymphocytic leukemia. J Immunol 1997;158:1482-1489.
5. P orakishvili N, Roschupkina T, Kalber T, et al. Expansion of CD4 T cells wiTha cytotoxic phenotype in patients wiThB-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol 2001;126:29-36.
6. V an den Hove LE, Vandenberghe P, Van Gool SW, et a l. Peripheral blood lymphocyte subset shifts in patients wiThuntreated hematological tumors: Evidence for systemic activation of the T cell compartment. Leuk Res 1998;22:175-184.
7. Goolsby CL, Kuchnio M, Finn WG, et a l. Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3 CD8 T-cell population. Cytometry 2000;42:188-195.
8. B riggs PG, Kraft N, Atkins RC. T cells and CD45R expression in B-chronic lymphocytic leukemia. Leuk Res 1990;14:155-159.
9. Rezvany MR, Jeddi-Tehrani M, Osterborg A, et a l. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: Major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999;94:1063-1069.
10. Farace F, Orlanducci F, Dietrich PY, et a l. T cell repertoire in patients wiThB chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. J Immunol 1994;153:4281-4290.
11. Buhmann R, Nolte A, Westhaus D, et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates diff erent types of eff ector cells. Blood 1999;93:1992-2002.
12. Krackhardt AM, Harig S, Witzens M, et al. T-cell responses against chronic lymphocytic leukemia cells: Implications for immunotherapy. Blood 2002;100:167-173.
13. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4 CD25hi regulatory T cells in patients wiThchronic lymphocytic leukemia after therapy wiThfl udarabine. Blood 2005;106:2018-2025.
14. Jak M, Mous R, Remmerswaal EB, et al. Enhanced formation and survival of CD4- CD25hi Foxp3 T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788-801.
15. Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and eff ector human CD8 T cells. J Exp Med 1997;186:1407-1418.
16. M ackus WJ, Frakking FN, Grummels A, et al. Expansion of CMVspecifi c CD8 CD45RA. Blood 2003;102:1057-1063.
17. G amadia LE, Rentenaar RJ, Baars PA, et al. Diff erentiation of cytomegalovirus-specifi c CD8 T cells in healthy and immunosuppressed virus carriers. Blood 2001;98:754-761.
18. Appay V, Zaunders JJ, Papagno L, et al. Characterization of CD4 CTLs ex vivo. J Immunol 2002;168:5954-5958.
19. van Leeuwen EM, Remmerswaal EB, Vossen MT, et al. Emergence of a CD4 CD28 granzyme B , cytomegalovirus-specifi c T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004;173:1834-1841.
20. Pourgheysari B, Bruton R, Parry H, et a l. Levels of cytomegalovirusspecifi c CD4- T cells are markedly expanded in patients wiThB-cell chronic lymphocytic leukaemia and determine the total CD4 T cell repertoire. Blood 2010;116:2968-2974.
21. Boom R, Sol C, Weel J, et al. A highly sensitive assay for detection and quantitation of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence. J Clin Microbiol 1999;37: 1489-1497.
22. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without eff ector function. J Exp Med 1998;188:2205-2213.
23. Lang KS, Moris A, Gouttefangeas C, et al. High frequency of human cytomegalovirus (HCMV)-specifi c CD8 T cells detected in healthy CMV-seropositive donor. Cell Mol Life Sci 2002;59:1076-1080.
24. Barber DL, Wherry EJ, Masopust D, et a l. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687.
25. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-126.
26. C hen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-347.
27. Xerri L, Chetaille B, Seriari N, et a l. Programmed deaTh1 is marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008;39:1050-1058.
28. Gorgun G , Holderried TA, Zahrieh D, et a l. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 cells. J Clin Invest 2005;115:1797-1805.
29. R amsay AG, Johnson AJ, Lee AM, et a l. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed wiThan immunomodulating drug. J Clin Invest 2008;118:2427-2437.
30. R amsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired wiThlenalidomide: Implications for the tumor microenvironment and immunotherapy. Blood 2009;114:4713-4720.
31. C hristopoulos P, Pfeifer D, Bartholome K, et a l. Defi nition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011;117:3836-3846.
32. O estreich KJ, Yoon H, Ahmed R, et a l. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 2008;181:4832-4839.
33. W ong RM, SmithKA, Tam VL, et al. TLR-9 signaling and TCR stimulation co-regulate CD8 T cell-associated PD-1 expression. Immunol Lett 2009;127:60-67.
34. K inter AL, Godbout EJ, McNally JP, et a l. The common gammachain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008;181:6738-6746.
35. Kater AP, Remmerswaal EB, Nolte MA, et al. Autologous cytomegalovirus-specifi c T cells as eff ector cells in immunotherapy of B cell chronic lymphocytic leukaemia. Br J Haematol 2004;126: 12-516.
36. N ishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11: 141-151.
37. K roner A, Mehling M, Hemmer B, et al. A PD-1 polymorphism is associated wiThdisease progression in multiple sclerosis. Ann Neurol 2005;58:50-57.
38. Hatachi S, Iwai Y, Kawano S, et al. CD4- PD-1- T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fl uid. J Rheumatol 2003;30:1410-1419.
39. N ielsen C, Hansen D, Husby S, et a l. Association of a putative regulatory polymorphism in the PD-1 gene wiThsusceptibility to type 1 diabetes. Tissue Antigens 2003;62:492-497.
40. Dearden C. Disease-specifi c complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008:450-456.
41. Akbar AN, Fletcher JM. Memory T cell homeostasis and senescence during aging. Curr Opin Immunol 2005;17:480-485 .